-
公开(公告)号：KR1020130126550A
公开(公告)日：2013-11-20
申请号：KR1020130053373
申请日：2013-05-10
Applicant: 가톨릭대학교 산학협력단
Abstract: The present invention relates to a bispecific antibody which is specific to IL-6R and TNF-alpha and a pharmaceutical composition containing the same for preventing and treating autoimmune diseases. The bispecific antibody of the present invention contains (a) an interleukin-6 receptor (IL-6R)-specific monoclonal antibody; and tumor necrosis factor receptor type 2 (TNFR2) proteins which is linked at C-terminal of a constant region of the monoclonal antibody or a fragment containing extracellular region of TNFR2 and is specific to IL-6R and TNF-alpha.
Abstract translation: 本发明涉及对IL-6R和TNF-α特异性的双特异性抗体以及含有该双特异性抗体的预防和治疗自身免疫疾病的药物组合物。 本发明的双特异性抗体含有（a）白细胞介素-6受体（IL-6R）特异性单克隆抗体; 和肿瘤坏死因子受体2型（TNFR2）蛋白，其在单克隆抗体的恒定区的C末端或含有TNFR2的胞外区的片段连接并且对IL-6R和TNF-α是特异性的。
-
22.发明公开항 ＩＬ-６Ｒ 및 ＴＮＦＲ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물 有权一种用于预防和治疗包含表达包含抗IL-6R和TNFR2的双向蛋白的微量载体的自身免疫性疾病的药物组合物
公开(公告)号：KR1020130126543A
公开(公告)日：2013-11-20
申请号：KR1020130053249
申请日：2013-05-10
Applicant: 가톨릭대학교 산학협력단
IPC: A61K48/00 , A61K39/395 , A61P37/00
CPC classification number: A61K48/00 , C12N15/63 , Y10S424/81 , Y10S514/825
Abstract: The present invention relates to a pharmaceutical composition containing a vector for treating immune diseases, which expresses bispecific proteins containing anti-IL-6R and TNFR2. The pharmaceutical composition of the present invention relates to a pharmaceutical composition for preventing and treating autoimmune diseases, containing (a) a gene expression cassette; (b) a site-specific recombinant region located at the outside of the gene expression cassette; and (c) a non-viral vector which does not contain a replication origin and a selection marker gene.
Abstract translation: 本发明涉及含有用于治疗免疫疾病的载体的药物组合物，其表达含有抗IL-6R和TNFR2的双特异性蛋白质。 本发明的药物组合物涉及含有（a）基因表达盒的自身免疫疾病的预防和治疗用药物组合物， （b）位于基因表达盒外侧的位点特异性重组区; 和（c）不含复制起点和选择标记基因的非病毒载体。
-
公开(公告)号：KR1020130126534A
公开(公告)日：2013-11-20
申请号：KR1020130053064
申请日：2013-05-10
Applicant: 가톨릭대학교 산학협력단
CPC classification number: Y02A50/473
Abstract: The present invention relates to a stem cell therapeutic agent containing a minicircle vector which expresses physiologically active proteins and, more particularly, to stem cells containing a minicircle vector which expresses physiologically active proteins and a pharmaceutical composition and a composition for drug delivery containing the same.
Abstract translation: 本发明涉及含有表达生理活性蛋白质的微循环载体的干细胞治疗剂，更具体地说，涉及含有表达生理活性蛋白质的微环载体的干细胞和药物组合物以及含有其的用于药物递送的组合物。
-
公开(公告)号：KR1020130063627A
公开(公告)日：2013-06-17
申请号：KR1020110130073
申请日：2011-12-07
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/08 , A23L33/10 , A61K33/00 , Y10S514/825
Abstract: PURPOSE: A composition containing marine minerals and essential inorganic salts for treating rheumatoid arthritis is provided to treat and alleviate rheumatoid arthritis. CONSTITUTION: A composition for treating rheumatoid arthritis contains marine mineral water which is collected underground at a depth of 1100 m at a hot spring of the coastal terrace 92-1, Geumjin-ri, Okgye-myeon, Gangneung-si, Ganwon-do in Korea. The mineral water is a concentrate water containing 200-230 mg/L of potassium, 7000-9500 mg/L of sodium, 1400-1700 mg/L of calcium, 900-1100 mg/L of magnesium, 3-9 mg/L of zinc, 25-35 mg/L of strontium, 200-500 Mg/L of selenium, 65-75 Mg/L of vanadium, 0.5-1.5 Mg/L of germanium, 10-40 Mg/L of manganese, 1-3 Mg/L of cobalt, 600-950 Mg/L of titanium, 3-9 Mg/L of copper, 0.02-0.09 mg/L of lithium, 16000-19500 mg/L of chlorine ion, 1.5-3.0 mg/L of fluorine ion, 40-56 mg/L of bromide ion, 3000-4500 mg/L of sulfate ion, 0.8-1.2 mg/L of boron, and 0.5-1.5 mg/L of silicon dioxide. The composition contains 0.5-50 wt% of the concentrate.
Abstract translation: 目的：提供含有海洋矿物质和治疗类风湿关节炎的必需无机盐的组合物，用于治疗和缓解类风湿性关节炎。 构成：用于治疗类风湿关节炎的组合物含有海水矿物质水，其在1100m深度的地下采集在甘肃省江陵市O ye，，jin仁海滨露台92-1的温泉处 韩国。 矿泉水是含有200-230mg / L的钾，7000-9500mg / L的钠，1400-1700mg / L的钙，900-1100mg / L的镁，3-9mg / L的浓缩水 的锌，25-35mg / L的锶，200-500Mg / L的硒，65-75Mg / L的钒，0.5-1.5Mg / L的锗，10-40Mg / L的锰，1- 3 Mg / L钴，600-950 Mg / L钛，3-9 Mg / L铜，0.02-0.09 mg / L锂，16000-19500 mg / L氯离子，1.5-3.0 mg / L 的氟离子，40-56mg / L溴离子，3000-4500mg / L硫酸根离子，0.8-1.2mg / L硼和0.5-1.5mg / L二氧化硅。 组合物含有0.5-50重量％的浓缩物。
-
25.发明授权
公开(公告)号：KR101266132B1
公开(公告)日：2013-05-27
申请号：KR1020100140600
申请日：2010-12-31
Applicant: 가톨릭대학교 산학협력단 , 주식회사 라이프사이언스테크놀로지
Abstract: 복수의단말기와공유서버및 실험프로토콜서버를포함하는디지털노트제작및 공유시스템에서수행되는디지털노트제작및 공유방법은, 제1 단말기는상기공유서버를통해상기실험프로토콜서버에접속하여실험프로토콜을선택하고, 선택된실험프로토콜을다운로드하는단계, 상기제1 단말기는상기실험프로토콜을기초로해당실험프로토콜에대한실험내용을입력받아디지털노트를만드는단계, 상기제1 단말기는상기디지털노트를상기공유서버에전송하는단계및상기공유서버는상기수신된디지털노트를기초로각 단말기의사용자에대한디지털노트소유리스트를업데이트하는단계를포함한다.
-
Patent Agency Ranking
公开(公告)号：KR102014020B1
公开(公告)日：2019-08-23
申请号：KR1020180007064
申请日：2018-01-19
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/077
-
公开(公告)号：KR101627045B1
公开(公告)日：2016-06-02
申请号：KR1020140134451
申请日：2014-10-06
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/505
Abstract: 본발명은메트포민및 스타틴의복합제를이용한자가면역질환의예방또는치료용조성물에관한것이다. 본발명에따른메트포민및 스타틴을유효성분으로포함하는복합제인자가면역질환의예방또는치료용약학적조성물은염증성사이토카인의생성을효과적으로억제시킬수 있고, 항체생산 B 세포의생성을저해또는활성을감소시킬수 있으며, 파골세포의분화를억제하고관절파괴를억제하는효과를가지며동맥경화반(Artherosclerotic plaque) 전구세포를형성하는거품세포(Foam cell)의생성억제효과가뛰어나메트포민및 스타틴을유효성분으로하는복합제는자가면역질환의치료제로서매우유용하게활용될수 있다.
-
公开(公告)号：KR101551926B1
公开(公告)日：2015-09-10
申请号：KR1020130107294
申请日：2013-09-06
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027 , C12N5/074 , C12N5/10
CPC classification number: A01K67/0278 , A01K67/0271 , A01K2207/12 , A01K2207/15 , A01K2227/105 , A01K2267/0387 , C12N5/0696 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/1392 , C12N2510/00
Abstract: 본발명은인간유래역분화줄기세포(induced pluripotent stem cell)를이용하여인간의면역계가발현된동물을제조하는방법, 및상기방법으로만들어진동물에관한것이다.
-
29.发明公开
公开(公告)号：KR1020130140557A
公开(公告)日：2013-12-24
申请号：KR1020130053097
申请日：2013-05-10
Applicant: 가톨릭대학교 산학협력단
CPC classification number: Y02A50/473
Abstract: The present invention relates to a stem cell therapeutic agent comprising a mini-circle vector expressing a dual-specific protein including anti-IL-6R and TNFR2 and, more specifically, to a stem cell comprising a mini-circle vector expressing a dual-specific protein including anti-IL-6R and TNFR2, and a pharmaceutical composition for treating autoimmune diseases including the same.
Abstract translation: 本发明涉及包含表达包含抗IL-6R和TNFR2的双重特异性蛋白质的微圆形载体的干细胞治疗剂，更具体地说，涉及包含表达双重特异性的微型圆形载体的干细胞 包括抗IL-6R和TNFR2的蛋白质，以及用于治疗包括其的自身免疫疾病的药物组合物。
-
公开(公告)号：KR1020130126549A
公开(公告)日：2013-11-20
申请号：KR1020130053356
申请日：2013-05-10
Applicant: 가톨릭대학교 산학협력단
CPC classification number: Y02A50/473 , A61K38/177 , A61K38/1774 , A61K48/00 , C07K14/70578 , C12N15/63 , Y10S514/825
Abstract: The present invention relates to a pharmaceutical composition containing a minicircle vector which expresses tumor necrosis factor receptor type 2 (TNFR2) for treating autoimmune diseases. The pharmaceutical composition of the present invention contains: (a) a gene expression cassette containing a promoter, a gene encoding TNFR2 proteins or a fragment containing extracellular region of TNFR2, and a terminator; b) a site-specific recombinant region located at the outside of the gene expression cassette; and a non-viral vector which does not contain a replication origin and a selection marker gene as active ingredients.
Abstract translation: 本发明涉及含有表达用于治疗自身免疫性疾病的2型肿瘤坏死因子受体（TNFR2）的小环载体的药物组合物。 本发明的药物组合物含有：（a）含有启动子，编码TNFR2蛋白的基因或含有TNFR2胞外区的片段的基因表达盒和终止子; b）位于基因表达盒外侧的位点特异性重组区; 和不含复制起点和选择标记基因作为活性成分的非病毒载体。
-
-
-
-
-
-
-
-
-
Search Results
58
records
(took 0.025 seconds)
